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Simultaneous recognition of HIV-1 TAR RNA bulge and loop
sequences by cyclic peptide mimics of Tat protein
Abstract
The interaction of the HIV-1 transactivator protein Tat with its transactivation response (TAR) RNA is
an essential step in viral replication and therefore an attractive target for developing antivirals with new
mechanisms of action. Numerous compounds that bind to the 3-nt bulge responsible for binding Tat
have been identified in the past, but none of these molecules had sufficient potency to warrant
pharmaceutical development. We have discovered conformationally-constrained cyclic peptide
mimetics of Tat that are specific nM inhibitors of the Tat-TAR interaction by using a structure-based
approach. The lead peptides are nearly as active as the antiviral drug nevirapine against a variety of
clinical isolates in human lymphocytes. The NMR structure of a peptide-RNA complex reveals that
these molecules interfere with the recruitment to TAR of both Tat and the essential cellular cofactor
transcription elongation factor-b (P-TEFb) by binding simultaneously at the RNA bulge and apical loop,
forming an unusually deep pocket. This structure illustrates additional principles in RNA recognition:
RNA-binding molecules can achieve specificity by interacting simultaneously with multiple secondary
structure elements and by inducing the formation of deep binding pockets in their targets. It also
provides insight into the P-TEFb binding site and a rational basis for optimizing the promising antiviral
activity observed for these cyclic peptides.
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Binding of the human immunodeficiency virus (HIV-1) transactivator protein Tat to its RNA 
response element (TAR) is an essential step in HIV replication and a potential target for 
novel antivirals. Past attempts to inhibit this interaction have identified numerous compounds 
that bind to the three nucleotide bulge responsible for binding Tat, but have failed to yield 
molecules with sufficient potency and specificity to warrant further pharmaceutical 
development. We have used a structure-based approach to discover conformationally-
constrained cyclic peptide mimetics of Tat that are specific nM inhibitors of the Tat-TAR 
complex. The NMR structure of the lead cyclic peptide bound to TAR reveals that the 
peptide targets not only the RNA bulge, but also the apical loop where the essential cellular 
cofactor p-TEFb binds, thereby interfering with the interaction between the host protein and 
the viral RNA as well. A conserved nucleotide in the apical loop stabilizes the peptide-RNA 
complex by covering the side of the peptide opposite the RNA major groove, thereby burying 
the peptide in a deeper pocket than observed in previous structures of TAR. This complex 
illustrates how small molecules and peptide mimics can achieve specificity in binding to 
RNA by inducing the formation of deep binding pockets in their target molecules and 
provides the first view of the apical loop of TAR forming a well-defined structure. It also 
provides a rational basis for optimization of the antiviral activity observed for these peptides 
against a variety of clinical isolates.  
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Introduction 
Transcription of the human immunodeficiency virus (HIV-1) RNA in infected cells is 
strongly activated by the complex formed by the viral Tat protein and its cognate 
transactivation response (TAR) RNA, a 59-nucleotide RNA found at the 5’ end of all nascent 
viral transcripts (Fig. 1a). Tat and its cellular co-factor, the transcription elongation factor-b 
(P-TEFb), are also required for reactivation of the integrated proviral genome in latently 
infected cells1. Tat and P-TEFb are recruited to the elongating RNA polymerase II (RNAP II) 
through interactions with TAR. The cooperative binding of Tat and P-TEFb to TAR activates 
the CDK9 kinase of P-TEFb that phosphorylates RNAP II as well as the repressive NELF 
factor(s), leading to greatly enhanced RNAP II processivity2,3.  
  The interaction between Tat and TAR is unique to the virus, while P-TEFb is 
utilized widely for transcription of most genes. The Tat-TAR complex is an attractive target 
to develop new antivirals for the following reasons: the specificity of the Tat-TAR complex 
to HIV-1; the extreme conservation of TAR amongst viral isolates; the critical role played by 
the P-TEFb cellular co-factor in promoting infectivity through the Tat-TAR complex; and the 
role of Tat and TAR in emergence from latency. These considerations have led to the 
evaluation of numerous small molecule and peptide-like inhibitors of the Tat-TAR interaction 
during the last 15 years4-6. However, none of these molecules had sufficient potency or 
selectivity to progress into pre-clinical studies. 
Inhibiting the Tat-TAR interaction is challenging for a variety of reasons. First, there 
is little precedent for the pharmacological disruption of protein-RNA complexes. Although 
the bacterial ribosome is a very well-validated drug target, most ribosome-binding antibiotics 
are large natural products with fairly unspecific binding activity for smaller RNAs. Mimicry 
of such compounds, often the aminoglycoside class of antibiotics, has not been fruitful. 
Second, RNA-protein interfaces are large; as with protein-protein interfaces, it remains 
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challenging, despite recent progress7, to inhibit these large interfaces with small drug-like 
molecules8,9. Third, the structure of the Tat-TAR complex has so far been inaccessible, 
although structures of TAR bound to a variety of small molecule ligands and Tat-derived 
peptides have been reported. These studies have convincingly demonstrated that Tat binding 
to TAR induces a characteristic conformational change that can be mimicked even by the 
binding of argininamide, but various critical aspects of the structure remain unclear, most 
significantly concerning the apical loop where p-TEFb binds. Finally, all compounds studied 
so far have targeted the three nucleotide bulge where Tat protein is known to bind; but have 
failed to interfere at the same time with P-TEFb binding to the apical loop of TAR.  
In seeking new approaches to inhibit viral transactivation, we explored structurally 
constrained peptides with the potential of targeting the UCU bulge and the apical loop 
simultaneously. Proteolytically stable peptide derivatives have been used previously to target 
TAR10-14. However, these linear peptide and peptide analogues were highly flexible and 
therefore bound various RNAs non-specifically, preventing the development of clear 
structure-activity relationships (SAR) or structural information. Thus, we focused our 
attention on the development of conformationally constrained mimics of HIV-1 Tat. We 
based the design of these compounds on the structure of the Bovine Immunodeficiency Virus 
(BIV) complex whose high resolution structure is available15-16. BIV Tat protein is highly 
homologous to HIV-1 Tat; as shown in Fig. 1, the two TAR RNAs also share very similar 
secondary structures. The successful structural mimicry of this protein using a 
conformationally constrained family of cyclic peptides that bound to BIV TAR RNA with 
nM affinity has been recently demonstrated17-18.  
In this manuscript, we report the discovery of a family of structurally constrained β-
hairpin cyclic peptide mimics of HIV-1 Tat protein that bind to TAR RNA with nM affinity 
and greatly improved specificity compared to previous small molecule or peptidic ligands. 
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The complex of one of the most potent peptides bound to TAR demonstrates that the peptides 
can interact with the apical loop as well as the UCU bulge. Unexpectedly, the interaction with 
the loop nucleotides buries the peptide into a much deeper groove than previously observed 
in any other structure of TAR. Formation of this deep groove relies upon an unpredicted role 
for a conserved looped-out nucleotide in stabilizing the peptide-RNA complex. The structure 
also validates the stable formation of a previously postulated19, but so far unobserved20-21, 
base triple near the bulge. Finally, the cyclic peptides employ a critically important bis-
arginine motif, which has observed previously in small molecule-TAR complexes, to induce 
conformational changes in the TAR bulge region. By defining the molecular basis for the 
high affinity and specificity of this new class of inhibitors targeting the Tat-TAR complex, 
the present structure provides a template for the structure-based optimization of this novel 
series of compounds. 
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Results 
Identification of nM inhibitors of the HIV-1 Tat-TAR interaction: The RNA-binding 
domain of BIV Tat protein forms a stable β-hairpin upon binding its cognate TAR15. We 
were able to use structure-based methods to discover low nM inhibitors of the Tat-TAR 
interaction in BIV17 by mimicking the β-hairpin with cyclic peptides stabilized by the 
heterochiral D-Pro-L-Pro template22-25 (Fig. 1c, d). In the absence of a structure for HIV Tat-
TAR complex, we reasoned that the same family of rigid cyclic peptides would also be able 
to act as HIV Tat inhibitors. Starting with the same cyclic peptide inhibitors of the BIV Tat-
TAR interaction17, we varied the amino acids on the peptide surface predicted to face the 
TAR RNA to optimize binding, while residues opposite to the predicted RNA-binding 
surface were varied to improve structural rigidity. Finally, we combined multiple individual 
amino acid changes that individually led to improved binding.  
Peptide binding to TAR was measured in vitro by electrophoretic mobility shift 
assays (EMSA). Fig. 2A presents EMSA data for L-22, one of the peptides with the strongest 
affinity for TAR (Kd=30 nM, Table 1) that also efficiently inhibits formation of the ADP-1-
TAR complex (Fig. 2B); ADP-1 is a 37-mer linear peptide containing the entire RNA-
binding activity of Tat protein20. EMSA experiments also demonstrated that L-22 inhibits 
formation of the complex between TAR RNA and a chimeric Tat/Cyclin T1 protein at sub-
micromolar concentrations (data not shown). Remarkably, binding to TAR could not be 
disrupted by even a 10,000 fold excess of tRNA present in the binding buffer (Fig. 2A), in 
contrast to linear peptides of similar length. 
Among the approximately 100 peptides investigated, three sequences stand out for 
their potency. L-22, L-50 and L-51 all have activity in the low nM range (Table 1); in fact, 
the Kd’s for L-50 and L-51 are well below 10 nM. The interaction is also highly specific: in 
addition to withstand competition from a 10,000-fold excess of tRNA (Fig. 2A), some of 
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these structures discriminate between HIV-1 and BIV TAR. For example, L-22 and L-51, 
which differ at only four positions, have binding affinities of 30 nM and 5 nM, respectively, 
for HIV-1 and of 5 nM and 50 nM, respectively, for BIV RNA. These results, in particular 
the selectivity of L-51 towards HIV-1 TAR, are remarkable given the similarities between the 
two RNAs and the origin of these peptides as structural mimics of BIV Tat. Equally 
satisfactorily, the results indicate that small changes in peptide sequence lead to significant 
changes in activity even for RNAs as closely related as the TAR RNAs from BIV and HIV-1. 
This is in marked contrast to previous linear peptidic and peptidomimetic inhibitors of HIV-1 
Tat-TAR, when changes in sequence generally led to only modest changes in activity and 
specificity against unrelated RNAs10,12. 
In order to understand the molecular basis for the activity of this class of peptide 
mimics, and to further improve their characteristics, we determined the structure of the L-22-
TAR complex. The L-22 peptide was selected for structure determination over L-50 and L-51 
due to the high quality of NMR data for its complex with TAR and the large number of 
intermolecular NOEs observed in NOESY spectra. 
 
Structure of the TAR-L-22 complex: The structure of the complex was determined by 
NMR spectroscopy as described in the methods section. Significantly, a total of 143 
intermolecular NOEs were assigned unambiguously to accurately define the relative position 
of the two molecules (Table 2). Remarkably, most arginine guanidinium NH2 protons were 
assignable from the combined analysis of filtered and conventional NOESY spectra; 
presumably, strong interactions with TAR slowed down bond rotation and exchange with 
solvent sufficiently to allow their observation. As a consequence, at least one intermolecular 
NOE was visible from the guanidinium group for every arginine residue. These observations 
facilitated precise positioning of each guanidinium group in the structure. 
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The L-22 peptide binds TAR in the major groove of the upper RNA helix (nucleotides 
26-29 and 36-39) with the D-Pro-L-Pro template facing down towards the lower helix. This 
orientation is analogous to what has been observed in the structure of the precursor peptide 
BIV-2 bound to BIV TAR RNA26 (Fig. 3a, b); this observation was important to the design of 
the HIV-directed library of peptides and it was reassuring to observe it in the final structure.  
 
The cyclic peptide makes intimate contacts with the apical loop of TAR, burying it from 
solvent into an unusually deep binding groove: An extremely interesting and surprising 
feature is the position of loop residue A35. It is flipped out from the RNA as in other 
structures of TAR4,19-21, but it is also drawn down in an unprecedented way towards the UCU 
bulge through an interaction with the guanidinium group of Arg11 (Fig. 3c), which resides 
near the D-Pro-L-Pro end of the peptide. In doing so, A35 draws other loop residues, 
particularly G33, to partially close around the peptide so as to create a much deeper binding 
pocket than observed in any other structure of TAR (Fig. 3d). In the present structure, the 
cyclic peptide is essentially surrounded with RNA residues. 
This unexpected interaction and the subsequent burial of the peptide deep into the 
RNA groove are key elements of the potency and selectivity of this class of peptides. In fact, 
replacement of Arg11 with even Lys in a peptide closely related to L-22, a substitution that 
obviously preserves charge, led to the loss of any detectable binding. A35 draws with it the 
RNA backbone between residues G33 and G34 to partially close over the strand of the 
peptide between Arg8 and Ile12, thereby deepening the binding pocket for the peptide. As a 
consequence of the interaction between A35 and Arg11, even Val2, which was postulated to 
remain solvent exposed when the peptides were designed, is partially protected from solvent 
by interacting with the minor groove face of A35.  
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Other interactions with the apical loop appear to be of less importance, and indeed the 
remainder of the loop remains locally unstructured (Fig. 3a). Specifically, the aliphatic 
portion of the Arg8 side chain interacts with the major groove face of G34, positioning the 
guanidinium group to stack on top of last base pair in the upper helix. The aliphatic portion of 
the Arg9 side chain lies instead next to the riboses of G33 and G34, and the corresponding 
guanidinium group interacts with the base of G33 as well. 
 
Hydrophobic interactions analogous to the BIV Tat-TAR complex stabilize the base triple 
and dock the peptide in the RNA groove - The present structure contains a base triple between 
U23 and the base pair A27/U38 in the upper helical stem, stabilized by hydrophobic and 
polar interactions with multiple amino acid side chains. The base triple had been proposed 
based on the structure of HIV-1 TAR RNA bound to argininamide19, but never directly 
observed with two hydrogen bonds in HIV-1 TAR; it is now clearly observed because the 
U23 NH resonance is protected from exchange and down field shifted upon formation of a 
hydrogen bond with A27 (Table 3). The NOE data indicate a canonical pairing for U23 and 
A27 in the base triple.  However, the U23 imino is shifted slightly away from linear hydrogen 
bond formation with the A27 N7 towards the exocyclic amino group. Both amino hydrogen 
atoms are protected from solvent exchange and observable in NOESY experiments.  Possible 
reasons for the stabilization of the base triple in this structure are discussed below. 
The presence of the base triple enables a continuously stacked pseudo-helical 
conformation between the upper and lower stems that progresses through the bulge. This 
occurs in spite of the extrusion of nucleotides C24 and U25 of the bulge away from the rest 
of the RNA, and is facilitated by a tight turn in the RNA backbone similar to what had been 
observed with argininamide and linear mimics of Tat protein20. Although U25 is flipped well 
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out into solution, NOE data reveals that the base of C24 interacts with the Lys6 side chain at 
the Lys-Gly turn, creating a small pocket for this residue by covering its solvent exposed 
surface opposite the major groove. Several strong intermolecular NOEs are visible in 
NOESY spectra between C24 H5 and H6 and the peptide residues Lys6, Arg5 and Thr4. 
          Two of the three hydrophobic residues within the peptide, Ile10 and Ile12, are buried in 
the RNA major groove as well. In particular, burial of the Ile10 methyls against the U23-
A27-U38 base triple closely imitates the role of Ile79 in the BIV Tat-TAR complex and of 
Ile10 in our BIV-2/BIV TAR structure, complexes upon which the L22 peptide was modeled. 
Significantly, the methyl groups of Ile10 are sequestered away in a pocket (Fig. 4a) that was 
also occupied by a benzoylic group in a small molecule complex with TAR27. Thus, this 
hydrophobic interaction likely drives base triple formation between U23 and the A27-U38 
Watson-Crick base pair as do the analogous interactions of Ile10 in the complex of the 
precursor peptide BIV-2 with BIV TAR RNA (Fig. 4b) and of Ile79 from the BIV Tat 
protein. No comparable isoleucine or hydrophobic residue exists within the basic region of 
HIV Tat (residues 48-57), but it is possible that a similar structural role could be played by 
residues from the hydrophobic stretch immediately to its N-terminus (Tyr47, Ile45, Leu43 or 
Phe38). Burial of the Ile10 and Ile12 hydrophobic groups, along with the aforementioned 
protection of Val2 by A35, leave very little of the hydrophobic surface area of the peptide 
exposed to solvent. Even the methyl group of Thr4 is partially protected by hydrophobic 
interactions with Gly7 in the β-turn at the tip of the structure.   
 
Polar interactions between Arg side chains occur with the base triple and around the bulge 
region of TAR: Multiple polar interactions involving Arg side chains and the RNA bases and 
phosphodiester backbone are observed at or near the bulge region of TAR. The guanidinium 
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group of Arg1 contacts the RNA backbone between G21 and A22 and is within hydrogen 
bonding distance of the A22 O2P atom (Fig. 5a). The guanidinium group of Arg3 establishes 
an electrostatic interaction with the U23 phosphate group and lies against the major groove 
edge of the A22 base. The aliphatic portion of the Arg5 side chain lies next to the ribose of 
U23, while the Arg5 guanidinium group stacks on top of the U23 base to provide a cation-π 
interaction (Fig. 5b), as assigned to a guanidinium group in close proximity (3.8 Å) to RNA 
bases and lying against one face of the aromatic system28. The interaction of Arg5 with U23 
is closely reminiscent of the upper half of a bis-arginine sandwich previously described in the 
complex of small molecule rbt203 with HIV-1 TAR RNA27. The guanidinium group of Arg5 
is approximately coplanar to the base of G28 and forms a hydrogen bond with the N7 of G28, 
and probably a second hydrogen bond to the O6 of G28 (Fig. 5c). We do not observe any 
interaction with the G26 major groove face, as had been postulated19,27. 
 
A Lys residue in the turn provides optimal electrostatic interactions with the phosphate 
backbone at the interhelical junction: In the design of our library of inhibitors, Lys6-Gly7 
and Gly6-Lys7 motifs were used alternately in the turn region to facilitate formation of a tight 
β-hairpin, yet Lys6-Gly7 was considerably more potent than Gly6-Lys7. The structure 
reveals that the Lys6-Gly7 arrangement unexpectedly contributes favorably to the binding 
energy. The charged terminus of the Lys6 side chain is positioned in a pocket of phosphate 
groups formed by the backbone atoms of C24, A27 and G28 (Fig. 5d). The aliphatic portion 
of the Lys6 side chain lies over Arg5, packing the guanidinium group against U23 (Fig. 5c), 
while itself being covered by the base of C24.  
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Discussion 
The Tat-TAR complex has long been considered an attractive target for the discovery 
of novel antivirals because of its central role in promoting infection by up-regulating HIV 
transcription. However, previous attempts to discover anti-Tat-TAR compounds with 
sufficient potency and selectivity to warrant pharmaceutical development have been 
unsuccessful10,12,27-33. Finding specific small molecule inhibitors of RNA-protein interactions 
is inherently difficult because of the large interfaces involved and of RNA flexibility. We 
reasoned that constrained peptides would provide more effective scaffolds to inhibit the 
relatively large interfaces between viral proteins and RNAs and would provide more specific 
ligands compared to linear peptide or peptide mimics due to their rigidity. Here we report the 
structure-based discovery of a family of proteolytically stable β-hairpin cyclic peptides that 
bind specifically to HIV-1 TAR RNA with low nM activity, as well as the structural basis for 
their activity and selectivity.  
The structural rigidity imposed by the D-Pro-L-Pro β-hairpin-inducing template locks 
the pharmacophores onto a β-hairpin structure with side chains emerging from each side. As 
a consequence of this rigidity, the most potent ligands discriminate very strongly against 
tRNA (>10,000 fold), and they also discriminate about 10-fold between RNAs that are as 
closely related as the TAR elements from BIV and HIV (Table 1). The highly specific 
binding of these molecules allowed them to compete with Tat protein and displace it from 
preformed complexes with TAR (Figure 2b). The structural rigidity and high affinity of the 
peptide lead to a stable TAR RNA conformation that has allowed us to determine a structure 
of TAR of unprecedented quality. 
The most surprising result was the observation that the peptide simultaneously 
organizes both the bulge and loop residues to partially close around it, creating a much 
deeper binding pocket than seen in all other structures of TAR. This conformation buries a 
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greater fraction of the peptide surface area than we would have predicted; approximately 51% 
of the peptide, invluding most of its hydrophobic side chains (Fig. 3d). The formation of a 
deep groove compared to free TAR or the ADP1-TAR complex is reminiscent of what has 
been observed with small molecule inhibitors of protein-protein interfaces7, which achieve 
high affinity by inducing the formation of deeper pockets within the contact surface 
compared to the protein-protein interface targeted for disruption. This structural feature is 
generated by the interaction between Arg11 in the peptide and A35, a highly conserved 
nucleotide that is bulged out in all structures of the TAR loop. While the G34-A35 region of 
the apical loop is rigidified by these interactions, the remainder of the loop remains flexible 
and makes no direct contact with the peptide. This observation suggests that improved 
potency may be obtained by further optimizing the peptide sequence to interact with the 
apical loop that is the binding site for the essential cellular co-factor p-TEFb. 
Binding of the peptide to the RNA also induces formation of a U23-A27-U38 base 
triple that was proposed more than 15 years ago19 but never directly observed in HIV-1 TAR. 
The base triple is conclusively identified by the observation of a signal from the U23 NH that 
is as stable to exchange with solvent as any of the Watson-Crick imino signals. Examination 
of the chemical shift data for U23 (the residue most affected by the conformational change) 
in various complexes reveals a much larger shift for L-22, relative to the free TAR, compared 
to the complexes with argininamide or ADP-1, suggesting that the conformational change has 
only been ‘completed’ in the present high affinity complex (Table 3). The NOE data identify 
a canonical UAU base triple without any disruption of the A27-U38 base pair34. While the 
hydrogen bond to the N7 was conclusively demonstrated for HIV-2 and HIV-1 TAR35-36 and 
was consistent with the previous structures of TAR bound to argininamide and Tat-derived 
peptide20, the second hydrogen bond was controversial because it is inconsistent with 
chemical interference data suggesting that chemical modification of the A27 amino group 
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does not lead to loss of ADP-1 binding to TAR37. It is possible that the base triple observed 
here is not present in the complex of HIV-1 Tat with TAR; however, it is also possible that 
Tat protein, in the absence of p-TEFb, only forms a highly dynamic complex with TAR that 
can tolerate modifications of its interaction with TAR as substantial as the disruption of the 
second hydrogen bond stabilizing the U23 base triple. 
 Stabilization of the base triple was proposed to occur through hydrogen bonds 
between argininamide and G26 as well as with a so-called ‘arginine fork’ involving the same 
guanidinium group and the phosphates of A22 and U2319,38. We do not see any evidence for 
this type of interaction in our complex, where base triple formation is driven instead by the 
burial of the hydrophobic side chain of Ile10 in the major groove of the RNA. This 
interaction is closely reminiscent of what has previously been observed with the BIV Tat-
TAR complex and recapitulated in our structure of BIV TAR with a related peptide mimic 
BIV-215, 26, as well as of the interaction of hydrophobic groups from small molecules with 
TAR4,27. In addition to Ile10, Arg5 forms a cation-π interaction with U23, reinforced by 
electrostatic interactions of Lys6 with A27 (above the base triple) and Arg3 below. Arg5 also 
forms a pair of hydrogen bonds with G28 above the base triple. 
As will be described in a subsequent manuscript, cyclic peptides in this family of 
compounds are potent inhibitors of viral replication which display many of the properties 
required for a promising drug lead.  First, the compounds are broad-spectrum HIV inhibitors 
and are active in human lymphocytes against a wide range of viral isolates from each of the 
HIV-1 clades.  Additionally, they show activities which are only 10-fold lower than the non-
nucleoside reverse transcriptase inhibitor neviparine in primary T-lymphocytes, and are not 
cytotoxic to the highest concentration tested (1 mM).  Finally, their rigid cyclic structure 
makes them stable to proteolysis. Mechanism-of-action studies show that the peptides do not 
inhibit HIV interaction with its receptor and viral entry, an off-target activity that prevented 
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the development of linear peptide and small molecule inhibitors of the Tat-TAR interaction33.  
Instead, the compounds appear to inhibit both early steps in reverse transcription and Tat-
dependent HIV transcription.  Thus, we are optimistic that cyclic peptides in this class will 
provide new antiviral drug leads active against a wide range of viral strains, including strains 
that are resistant to the current range of drugs. The structure presented here provides rational 
insight towards the optimization of the antiviral activity of this new class of TAR-RNA 
binding inhibitors. 
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Methods 
Peptide synthesis. The synthesis of the cyclic peptides was conducted as described 
previously39. The ADP-1 peptide containing the entire RNA-binding activity of Tat protein20 
was prepared on MBHA-Rink amide resin using Fmoc-chemistry on an Applied Biosystems 
433A peptide synthesizer.  
Binding assays. HIV-1 TAR RNA preparation, 3’-end labeling of TAR and EMSA assays 
were done as described previously39. Inhibition assays were performed in the same way but 
by pre-forming the complex of HIV TAR with the ADP-1 peptide (150 nM) prior to peptide 
addition and fractionation by electrophoresis.  
RNA synthesis. HIV-1 TAR RNA was prepared in vitro from commercially synthesized 
DNA templates (IDT) using in house purified T7 RNA polymerase and either unlabeled 
nucleotides (Sigma) or 98% 15N, 13C labeled nucleotides (Isotec) as described40. The DNA 
templates incorporated a 2’-O-methyl group on each of the two guanine nucleotides at the 5’ 
end of the DNA to reduce the production of products containing 1 or 2 additional nucleotides 
at the 3’-end41. The desired RNA product was purified by denaturing 20% polyacrylamide 
gel electrophoresis, followed by electroelution, desalting on a NAP-10 column, and extensive 
dialysis against a 10 mM potassium phosphate buffer, pH 6.6, with 0.1 mM EDTA. The RNA 
concentration was measured by UV absorbance at 260 nm. Partially perdeuterated RNA was 
generated by the same methods using 98% deuterated nucleotides (Isotec). 
 
Sample Preparation. Prior to each NMR experiment, the RNA samples were annealed by 
heating at 95 °C briefly then quick cooled on ice. Sample concentrations of approximately 
1mM were used for all NMR experiments, except the experiments on partially aligned RNA 
samples that were instead collected at a concentration of 0.6 mM. Samples for experiments 
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studying non-exchangeable protons were dissolved in 99.9% D2O and lyophilized three times 
before the final preparation in 99.99% D2O. Aliquots of 10 mM peptide solution were added 
to TAR; formation of a 1:1 complex was monitored by examination of the H5/H6 region of 
TOCSY spectra. The peptide was titrated into the RNA solution until a single set of 
pyrimidine peaks corresponding to the peptide-bound RNA was observed, establishing 
formation of a stoichiometric complex. 
NMR Spectroscopy. Most NMR spectra were collected on Bruker DRX 500 MHz , Bruker 
DMX 600 MHz, and a Varian Inova 800MHz spectrometers equipped with cryo-cooled HCN 
probes with triple-axis gradients. Experiments utilizing 31P were collected on a Bruker 
AVIII600 MHz with cryo-cooled HCP probe (Johann Wolfgang Goethe-University). Data 
were processed with NMRPipe42 and analyzed in Sparky43. NOESY experiments in D2O 
were recorded at three mixing times (100 ms, 200 ms and 300 ms). NOESY experiments 
recorded in water at 4 °C were collected with WATERGATE  solvent suppression44 and 
mixing times of 100 and 200 ms. The 3D 13C NOESY-HMQC spectra were recorded at 500 
Mhz with mixing times of 100 and 200 ms.  Carbon spectral widths were set to 24 ppm to 
fold ribose resonances back into an optimally minimized spectral window and improve 
resolution. The 2D 13C filtered NOESY and TOCSY  spectra of the “F1fF2f” type45-46 were 
collected at 600 MHz to facilitate assignments of peptide resonances overlapped with RNA 
resonances. The NOESY experiments were collected with a mixing time of 100 ms in both 
D2O and water; the TOCSY employed a 40 ms DIPSY-2 spin lock period. NOESY spectra 
using partially perdeuterated RNA (with only H6/8, H2, H1’, and H2’ protons present) were 
collected at 800 MHz with mixing times of 150 ms and 300 ms. The sharper line widths for 
these samples facilitated assignment of both intra- and inter-molecular NOEs. 3D HCP and 
3D 13C edited 1H/31P HETCOR experiments were collected using standard methods and were 
used in the determination of backbone dihedral angles and 31P assignments40.  
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Spectral Assignments: Resonance assignments were already available for free HIV-1 TAR 
RNA and for TAR bound to a single argininamide and to the ADP-1 peptide20. Comparison 
of 1H-1H NOESY spectra for the free and peptide-bound RNA revealed several unchanged 
proton chemical shifts near the 5’ and 3’ ends of the RNA; these residues are not involved in 
binding to the peptide. These observations, along with clearly identifiable adenine H2 proton 
resonances, were used to generate initial proton assignments. HCCH-COSY, HCCH-TOCSY, 
and HSQC-NOESY experiments were collected to complete proton assignments and to 
generate carbon chemical shift assignments. The 15N chemical shifts were assigned for base-
paired nucleotides using a 15N HSQC experiment.  
 Initial proton assignments for the peptide were made from F1fF2f NOESY spectra 
recorded in water. These assignments were generated from the observation of the typical (i to 
i+1) pattern of NOEs for sequential Hα and HN protons common in β-sheets 46. Assignments 
were completed with F1fF2f TOCSY in D2O and 2D NOESY in D2O with the partially 
perdeuterated RNA, that removed much of the overlap between peptide and sugar resonances 
and also provided sharper, more distinguishable cross-peaks for the peptide. A natural 
abundance 13C HMQC experiment collected with unlabeled peptide-RNA complex was used 
for assignment of 13C resonances in the peptide. 
Residual Dipolar Couplings (RDCs): In-Phase-Anti-Phase (IPAP) HSQC data were 
collected for an unaligned sample of TAR/L-22 complex as a reference spectrum47. The 
sample was then partially aligned using Pf1 phage (Asla Ltd.) in water to a final 
concentration of 21 mg/mL phage and dialyzed extensively against a 10 mM phosphate 
buffer, pH 6.6 in 99.9% D2O. The IPAP experiment was repeated for this partially aligned 
sample. Heteronuclear one-bond 1H/13C couplings were measured from the IPAP data in the 
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presence (Jpf1) and absence of phage (Jnopf1). RDC values were determined using the equation 
RDC= Jpf1- Jnopf1. 
Structure Determination: Structures of the HIV-1 TAR RNA/L-22 complex were 
calculated with Xplor-NIH software using torsion angle dynamics and simulated annealing48. 
Distance restraints were established from NOE intensities in 2D NOESY spectra at 100 ms 
mixing time and from 3D NOESY-HSQC spectra at 100 ms mixing time for resonances 
overlapped in the 2D NOESY. Standard planarity and hydrogen bond restraints were applied 
to unambiguously base-paired nucleotides, as identified from NOESY spectra in water. The 
imino proton of U23 was clearly hydrogen bonded, because a sharp resonance was observed 
in the water NOESY spectra; however, the interaction between U23 and A27/U38 was not 
constrained by any hydrogen bond restraint until structure calculations based entirely on 
NOEs consistently showed that U23 was poised to make two hydrogen-bonds between U23 
O4 and A27 HN’’ and U23 H3 and A27 N7.  Loose restraints on backbone dihedral angles 
(+/- 40°) were introduced for base-paired regions in both stems based upon spectroscopic 
verification of an A-form RNA conformation and as determined experimentally from the 
pattern of cross-peaks in 2D TOCSY, TOCSY-HSQC, 3D HCP, and 3D phosphorus 
HETCOR experiments40. Dihedral angle restraints for the bulge and loop nucleotides were 
experimentally established, whenever possible, using the same experimental approach. The 
strength of the intranucleotide H1’-H8 peak was used to restrain the glycosidic angle, while 
the sugar puckers were determined from the intensity of the H1’-H2’ coupling in 3D 
TOCSY-HSQC, and β and ε dihedral angles were established from the magnitudes of 3JCP 
and 3JHP couplings in HCP experiments. Backbone dihedral angle restraints for the peptide 
were estimated using chemical shift data and TALOS prediction software49.  
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Structures were originally calculated without RDCs to test for convergence and adherence to 
the NOE data. RDC restraints were then applied as susceptibility anisotropy (‘sani’) restraints 
with a harmonic potential well. Only RDCs of the two stem regions were used for the initial 
refinement. The powder pattern-like distribution of RDCs50  was used to calculate starting 
values for Da and R of approximately -20 and 0.3, respectively. Optimal values of Da and R 
were then established by a grid search; the lowest energy structures were found for Da=-30 
and R=0.25. A 15-20% discrepancy between the Da estimated from the powder-like pattern 
of RDCs and the actual value of Da is common, due to the low probability of finding a bond 
vector that makes an angle �=0° to the z-axis of the alignment tensor51. These parameters 
were used in subsequent refinement on calculations of the final 100 structures. The final 10 
converged structures of the complex were selected from the population of structures with no 
NOE restraint violations greater that 0.5 Å and the lowest violations of all experimental 
restraints. 
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Table 1: Sequences of the lead peptides L-22, L-50 and L-51 and summary of their activity 
(Kd values are in nM) for their interaction with HIV-1 and BIV TAR, as determined by 
EMSA. 
Mimetic     Position        Kd 
(HIV) 
Kd 
(BIV) 
 1 2 3 4 5 6 7 8 9 10 11 12   
L-22 R V R T R K G R R I R I 30 5 
L-50 R V R T R G K R R I R R 1 1 
L-51 R T R T R G K R R I R V 5 50 
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Table 2: Experimental restraints and structural statistics for the L22-TAR complex 
Total number of restraints 1107 
Average number of restraints per hydrogen atom 2.3 
NOE-derived restraints  809 
     intermolecular NOEs 143 
     RNA (intramolecular) 464 
     peptide (intramolecular) 204 
Dihedral restraints 193 
Dipolar coupling restraints 25 
Hydrogen-bonding restraints 66 
Planarity restraints 12 
Average rmsd values from experimental restraints  
     distance (Å) 0.02 
     dihedral (deg) 0.89 
     RDC (Hz) 0.49 
Average rmsd values from ideal geometries  
     bonds (Å) 0.003 
     angles (deg) 0.64 
     improper (deg) 0.50 
Heavy atom rmsd from mean structure (Å)  
     L-22 (all backbone atoms) 0.33 
     L-22 (all heavy atoms) 0.98 
     TAR RNA (all heavy atoms) 1.9 
     TAR RNA core (G18-U23, G26-C29, G36-C44) 0.64 
     L-22 and TAR core 0.86 
     entire structure 1.9 
 
 
 
 
Table 3: Chemical shift data for U23 base protons from several TAR complexes. 
Ligand HN H5 H6 
None 10.8 5.5 7.5 
Argininamide Not 5.6 7.5 
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observed 
ADP-1 Not 
observed 
5.5 7.6 
L-22 14.2 5.1 7.9 
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Figure Captions 
Figure 1: (a) Sequence and secondary structure of the HIV TAR construct used in NMR 
studies, numbered according to the start of transcription of the viral RNA; (b) Sequence and 
secondary structure of the BIV TAR construct35; (c) Sequence of the L-22 peptide; (d) 
Structure of the D-Pro-L-Pro template used to constrain the peptide to a stable β-hairpin 
conformation. 
 
Figure 2: Binding of cyclic peptides to HIV-1 TAR and inhibition of the Tat-TAR complex 
studied by electrophoretic mobility shift assays (EMSA): (a) Binding of L-22 peptide (all 
concentrations are in µM) to HIV TAR (1 nM); the buffer contains a 10,000 fold excess of 
tRNA to ensure that the observed binding is specific; (b) Inhibition of the complex between 
the ADP-1 peptide (150 nM) and HIV TAR (1 nM) by L-22, in the presence of same 10,000-
fold excess of tRNA. 
 
Figure 3: a) Structure of the HIV-1 TAR/L-22 complex. The orientation of the peptide is 
identical to the structure observed in the complex between BIV TAR and a related peptide35 
(shown in part b). c) The base of nucleotide A35, which is normally flipped into solution, is 
oriented toward the D-Pro-L-Pro end of the peptide and interacts with Arg11. The RNA is 
represented as a gray surface with nucleotides of interest in purple; the peptide is in orange. 
d) The peptide does not simply stick into the major groove (right), but organizes the bulge 
and loop residues to partially close around it, creating a much deeper binding pocket than 
seen in other structures of TAR, such as the structure of free TAR (left) or TAR bound by 
argininamide (center). 
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Figure 4: Hydrophobic interactions of peptide side chains into the RNA groove stabilize 
formation of the base triple. (a) The hydrophobic side chain of Ile10 is sequestered away in a 
pocket formed by the bases of U23, U38 and A27 and make extensive packing interactions 
with the two uracyls; (b) An analogous interaction was observed in the complex of BIV-2 
with BIV TAR RNA between Ile10 and the U10 and U24 bases. The RNA and peptide are 
represented as in Fig. 3; the Van der Waals surface of the Ile10 side chain is represented in 
dots. 
 
Figure 5: Polar interactions between Arg and Lys side chains and the RNA bases and 
backbone at or near the TAR bulge; the RNA and peptide are represented as in Fig. 3. a) The 
guanidinium group of Arg1 contacts the RNA backbone between G21 and A22 and is within 
hydrogen-bonding distance of the A22 phosphate (dotted line); b) The Arg5 guanidinium 
group stacks on top of the U23 base to provide a cation-π interaction that stabilizes the base 
triple (hydrogen bonds are shown by dotted lines), while the aliphatic portion of the Lys6 
side chain lies over Arg5, packing its guanidinium group against U23; c) Arg5 is also 
approximately coplanar to the base of G28, forming canonical Arg-Guanine hydrogen bonds 
with the O6 and N7 of G28. d) Polar interactions between the side chain of Lys6 and the 
RNA backbone. The Lys6 amine is buried in a region of deep negative electrostatic potential 
formed by the phosphates of C24, A27 and G28. 
 
